Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
30 Apr 24
DEF 14A
Definitive proxy
30 Apr 24
8-K
Other Events
30 Apr 24
EFFECT
Notice of effectiveness
24 Apr 24
8-K
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating
17 Apr 24
8-K
Other Events
16 Apr 24
S-3
Shelf registration
12 Apr 24
8-K
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
1 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
28 Mar 24
8-K
Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification
13 Mar 24
8-K
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive
4 Mar 24
8-K
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
29 Feb 24
8-K
Other Events
14 Feb 24
8-K
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
1 Feb 24
8-K
Full Data Readout Expected in the Second Half of 2024
18 Jan 24
8-K
Other Events
9 Jan 24
8-K
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
28 Dec 23
8-K
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
19 Dec 23
8-K
Regulation FD Disclosure
7 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
Departure of Directors or Certain Officers
6 Nov 23
8-K
Departure of Directors or Certain Officers
30 Oct 23
8-K
Regulation FD Disclosure
22 Sep 23
8-K
Departure of Directors or Certain Officers
19 Sep 23
8-K
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
15 Sep 23
8-K
Entry into a Material Definitive Agreement
24 Aug 23
8-K
Neurobo Pharmaceuticals Appoints Hyung Heon Kim
14 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
9 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Aug 23
8-K
NeuroBo Pharmaceuticals Receives First Site IRB Approval for its
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
29 Jun 23
8-K
Other Events
27 Jun 23
8-K
Other Events
13 Jun 23
8-K
Other Events
2 Jun 23
ARS
2022 FY
Annual report to shareholders
26 May 23
DEF 14A
Definitive proxy
26 May 23
PRE 14A
Preliminary proxy
16 May 23
Latest ownership filings
4
Marshall H Woodworth
4 Mar 24
4
James Patrick Tursi
4 Dec 23
3
James Patrick Tursi
2 Nov 23
3
Marshall H Woodworth
30 Oct 23
4
Hyung Heon Kim
14 Aug 23
4
ANDREW I KOVEN
28 Jul 23
4
Michael Salsbury
28 Jul 23
4
D GORDON STRICKLAND
28 Jul 23
4
JASON L GROVES
28 Jul 23
4
Mark A Glickman
28 Jul 23
4
Na Yeon Kim
28 Jul 23
4/A
Na Yeon Kim
28 Jul 23
3
Mark A Glickman
12 May 23
SC 13G
Strategic Risk, LLC.
28 Mar 23
SC 13G/A
Altium Capital Management LP
14 Feb 23
3
Joseph Hooker
18 Jan 23
SC 13D/A
DONG-A ST CO., LTD
30 Dec 22
3
Initial statement of insider ownership
22 Nov 22
SC 13G
Altium Capital Management LP
17 Nov 22
SC 13D/A
DONG-A ST CO., LTD
10 Nov 22
SC 13D/A
JK BioPharma Solutions, Inc
23 Sep 22
SC 13D/A
DONG-A ST CO., LTD
16 Sep 22
SC 13D/A
E&Investment, Inc.
5 Aug 22
4
Investment Fund II E&Healthcare
28 Jul 22
4
Na Yeon Kim
28 Jul 22
4
Na Yeon Kim
13 Jun 22
4
JASON L GROVES
13 Jun 22
4
Hyung Heon Kim
10 Jun 22
4
Richard Kang
10 Jun 22
4
D GORDON STRICKLAND
10 Jun 22
4
Michael Salsbury
10 Jun 22
4
ANDREW I KOVEN
10 Jun 22
4
D GORDON STRICKLAND
2 Feb 22
3
D GORDON STRICKLAND
2 Feb 22
SC 13D/A
JK BioPharma Solutions, Inc
10 Nov 21
4
Ben Gil Price
4 Nov 21
3
Ben Gil Price
4 Nov 21
4
ANDREW I KOVEN
3 Sep 21
SC 13D/A
DONG-A ST CO., LTD
1 Sep 21
SC 13D/A
E&Investment, Inc.
30 Aug 21